Latest Articles

Publication Date
Prenatal bisphenol A exposure reprograms SF1-lactylation pathways to promote endometriosis susceptibility.

Endometriosis is an estrogen-dependent disorder influenced by dysregulated steroidogenesis, oxidative stress, and inflammation. Bisphenol A (BPA), a common endocrine disruptor, has been associated with reproductive dysfunction, but its developmental impacts …

Published: April 4, 2026, midnight
Major postoperative complications after endometriosis surgery: incidence and outcomes from a multicenter French cohort.

Surgery is a therapeutic option for patients with deep endometriosis presenting with infertility and/or pain refractory to medical treatment. Major postoperative complications may impair quality of life and delay the …

Published: April 3, 2026, midnight
Correlation Between Pain Intensity in Different Locations and Intraoperative Stage of Endometriosis According to rASRM and #ENZIAN Classification.

Background/Objectives: Endometriosis is a chronic inflammatory disease with a heterogeneous clinical presentation, in which pain represents the predominant symptom. The association between pain severity and intraoperative disease stage remains unclear, …

Published: April 3, 2026, midnight
Contemporary Diagnostic and Therapeutic Approaches in Endometriosis: A Systematic Review.

Endometriosis is a chronic inflammatory disorder characterized by pelvic pain, infertility, and reduced quality of life, and is frequently associated with prolonged diagnostic delay and variable treatment response. Although advances …

Published: April 3, 2026, midnight
Single-Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non-Pregnant, Non-Lactating Premenopausal Female Subjects Under Fasting Conditions.

Elagolix is a short-acting oral gonadotropin-releasing hormone antagonist utilized for treating endometriosis-associated pain by rapidly suppressing gonadotropins and estradiol. Although well characterized in Western populations, clinical data regarding its use …

Published: April 2, 2026, midnight
Adenomyosis Pathophysiology, Diagnostic Advances, and Therapeutic Options.

Adenomyosis is a heterogeneous, nonmalignant uterine disorder characterized by ectopic endometrium within the myometrium, leading to abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and subfertility. Once considered a disease of …

Published: April 2, 2026, midnight
Thoracic endometriosis in an inoperable patient.

In this case report, we present a case of a woman in her 30s who was diagnosed with thoracic endometriosis presenting as a large pulmonary mass. Hormonal treatment progestin (synthetic …

Published: April 2, 2026, midnight
An Immunomodulating Peptide With Potential to Counteract Endometriosis.

Endometriosis is underpinned by dysfunctional immune responses resulting in failure to clear ectopic endometrial lesions from the peritoneal cavity. The pelvic milieu comprising immature dendritic cells, dysfunctional cytotoxic lymphocytes, and …

Published: April 1, 2026, midnight
Diagnostic test accuracy of each of the four IDEA ultrasound steps in predicting presence of deep endometriosis.

To determine the diagnostic performance of each additional step of the four-step International Deep Endometriosis Analysis (IDEA) consensus protocol for predicting the presence of deep endometriosis (DE) on transvaginal ultrasound.

Published: April 1, 2026, midnight
Menopausal hormone use after hysterectomy in endometriosis: a Finnish register-based study.

This study aimed to examine the frequency and type of menopausal hormone therapy (MHT) use after hysterectomy among women with surgically diagnosed endometriosis.

Published: April 1, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!